AIP
ARQT icon

Ameritas Investment Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Ameritas Investment Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Buy
10,386
+1,438
+16% +$33.5K 0.01% 1210
2026
Q1 		$211K Hold
8,948
– – 0.01% 1237
2025
Q4 		$260K Hold
8,948
– – 0.01% 1107
2025
Q3 		$169K Sell
8,948
-2,297
-20% -$36.2K 0.01% 1330
2025
Q2 		$158K Hold
11,245
– – 0.01% 1454
2025
Q1 		$176K Hold
11,245
– – 0.01% 1339
2024
Q4 		$157K Buy
11,245
+837
+8% +$9.17K 0.01% 1480
2024
Q3 		$96.8K Hold
10,408
– – ﹤0.01% 1819
2024
Q2 		$96.8K Buy
10,408
+2,537
+32% +$22.9K ﹤0.01% 1749
2024
Q1 		$78K Buy
7,871
+2,800
+55% +$20.9K ﹤0.01% 1892
2023
Q4 		$16.4K Hold
5,071
– – ﹤0.01% 2674
2023
Q3 		$26.9K Buy
5,071
+825
+19% +$7.02K ﹤0.01% 2412
2023
Q2 		$40.5K Buy
4,246
+1,042
+33% +$11.6K ﹤0.01% 2167
2023
Q1 		$35.2K Hold
3,204
– – ﹤0.01% 2191
2022
Q4 		$52.3K Hold
3,204
– – ﹤0.01% 2023
2022
Q3 		$61K Buy
3,204
+577
+22% +$13.1K ﹤0.01% 1831
2022
Q2 		$55K Buy
2,627
+747
+40% +$15.3K ﹤0.01% 1926
2022
Q1 		$36K Hold
1,880
– – ﹤0.01% 2246
2021
Q4 		$39K Hold
1,880
– – ﹤0.01% 2287
2021
Q3 		$45K Hold
1,880
– – ﹤0.01% 2229
2021
Q2 		$51K Hold
1,880
– – ﹤0.01% 2162
2021
Q1 		$54K Buy
1,880
+340
+22% +$10.6K ﹤0.01% 2034
2020
Q4 		$43K Hold
1,540
– – ﹤0.01% 2070
2020
Q3 		$45K Buy
1,540
+643
+72% +$17.2K ﹤0.01% 1905
2020
Q2 		$27K Hold
897
– – ﹤0.01% 2173
2020
Q1 		$27K Buy
+897
New +$24.1K ﹤0.01% 1999

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ameritas Investment Partners's ARQT Position: Q2 2026 in Review

Ameritas Investment Partners increased its Arcutis Biotherapeutics (ARQT) stake by 16% in Q2 2026, buying an estimated $33.5K and bringing the position to 10,386 shares worth $272K. The position accounts for 0.01% of the portfolio, ranked #1210.

Ameritas Investment Partners first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Ameritas Investment Partners held 10,386 shares of Arcutis Biotherapeutics worth $272K as of Q2 2026.
  • Ameritas Investment Partners bought 1,438 Arcutis Biotherapeutics shares in Q2 2026, an estimated $33.5K.
  • Arcutis Biotherapeutics made up 0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1210 holding.
  • Ameritas Investment Partners first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.